drugset / Trial / NCT03935971
The Effects of Dupilumab on Allergic Contact Dermatitis
Phase 4
Active not recruiting
17 enrolled
Brigham and Women's Hospital
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
Timeline
- Start
- 2019-12-18
- Primary completion
- 2024-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |